This activity is supported by an educational grant from Lilly.
Meet the Faculty:
Anna D. Burke, MD
Karsten Solheim Chair for Dementia
Director of Alzheimer’s and Memory Disorders Division
Karsten Solheim Chair for Dementia
Director of Alzheimer’s and Memory Disorders Division
Director of Neuropsychiatry
Department of Neurology
Barrow Neurological Institute
Phoenix, AZ
Abstracts:
Donanemab in Early Symptomatic Alzheimer’s Disease: Additional Insights from TRAILBLAZER-ALZ 2, Chair: Takeshi Iwatsubo, The University of Tokyo, Tokyo (Japan)
1. Safety Insights from the Donanemab Trials, Steve Greenberg, Harvard Medical School and Massachusetts General Hospital, Boston, MA (United States)
2. Predicting Efficacy in Donanemab-Treated Participants, Mark Mintun, Eli Lilly and Company, Indianapolis, IN and Avid Radiopharmaceuticals, Inc. Philadelphia, PA (United States)
Lecanemab for Early Alzheimer’s Disease: Long-Term Outcomes, Predictive Biomarkers and Novel Subcutaneous Administration, Chair: Christopher van Dyck, Yale Alzheimer’s Disease Research Center – New Haven (United States)
1. Clarity AD: Review of the Mechanism-Based Rationale and Results of the Lecanemab Phase 3 Trial, Christopher van Dyck, Yale Alzheimer’s Disease Research Center – New Haven (United States)
2. Biomarker Assessments from Clarity AD: Downstream Implications of Targeting Protofibrils and Tau as a Predictive Biomarker, Keith Johnson, Harvard Medical School – Boston (United States)
3. Lecanemab for the Treatment of Early Alzheimer’s Disease: The Extension of Efficacy Results from Clarity AD, Reisa Sperling, Brigham and Women’s Hospital Harvard Medical School – Boston (United States)
4. Preliminary Update on Lecanemab Safety in Clarity AD Open-Label Extension, Including Subcutaneous Formulation, Michael Irizarry, Eisai Inc. – Nutley (United States)
Earn credit by taking a few minutes to participate in CME Outfitters Reinforcing Reflections, a text-based reflection of how a topic or concept connects to your clinical practice & professional life.